HAEK — Haemato AG Share Price
Last trade - 00:00- €70.88m
- €47.91m
- €248.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.05 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -4.13% | ||
| Dividend Yield (f) | 9.56% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 1.22 | ||
| Price to Free Cashflow | 6.91 | ||
| Price to Sales | 0.27 | ||
| EV to EBITDA | 4.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.03% | ||
| Return on Equity | 6.51% | ||
| Operating Margin | 3.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 274.12 | 197.83 | 238.33 | 285.04 | 248.14 | 268.15 | 274.4 | -3.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -13.62 | n/a | n/a | n/a | +22.17 | -4.13 | +27.1 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company operates in two segments specialty pharma and lifestyle and aesthetics. Specialty pharma segment includes the trade and production of drugs and preparations in the field of human immunodeficiency virus (HIV), oncology, rheumatology, neurology as well as cardiovascular diseases and other chronic diseases. Its lifestyle and aesthetics segment is an outcome of new subsidiary M1 Aesthetics GmbH which is into marketing of pharmaceutical, medical and med tech products for aesthetic surgery and cosmetic dermatology. The Company acts as a wholesaler and parallel importer. Its business is carried out by there companies Haemato pharma AG, Haemato Med GmbH, M1 Aesthetics GmbH. It offers related support services.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- April 28th, 2003
- Public Since
- March 26th, 2012
- No. of Employees
- 78
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Hamburg Stock Exchange
- Shares in Issue
- 5,212,106
- Address
- Lilienthalstrasse 3a, SCHOENEFELD, 12529
- Web
- https://haemato.ag/
- Phone
- +49 30897308670
- Auditors
- Gieron and Partner GmbH
Upcoming Events for HAEK
Similar to HAEK
MediNavi AG
Hamburg Stock Exchange
FAQ
As of Today at 20:59 UTC, shares in Haemato AG are trading at €13.60. This share price information is delayed by 15 minutes.
Shares in Haemato AG last closed at €13.60 and the price had moved by -20.93% over the past 365 days. In terms of relative price strength the Haemato AG share price has underperformed the FTSE Global All Cap Index by -22.91% over the past year.
The overall consensus recommendation for Haemato AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Haemato AG dividend yield is 8.82% based on the trailing twelve month period.
Last year, Haemato AG paid a total dividend of €1.20, and it currently has a trailing dividend yield of 8.82%. We do not have any data on when Haemato AG is to next pay dividends.
We do not have data on when Haemato AG is to next pay dividends. The historic dividend yield on Haemato AG shares is currently 8.82%.
To buy shares in Haemato AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €13.60, shares in Haemato AG had a market capitalisation of €70.88m.
Here are the trading details for Haemato AG:
- Country of listing: Germany
- Exchange: HAM
- Ticker Symbol: HAEK
Based on an overall assessment of its quality, value and momentum Haemato AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Haemato AG is €35.00. That is 157.35% above the last closing price of €13.60.
Analysts covering Haemato AG currently have a consensus Earnings Per Share (EPS) forecast of €1.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Haemato AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -3.67%.
As of the last closing price of €13.60, shares in Haemato AG were trading -0.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Haemato AG PE ratio based on its reported earnings over the past 12 months is 9.05. The shares last closed at €13.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Haemato AG's management team is headed by:
- Andrea Grosse - CSU
- Sabine Meck - VSU
- Daniel Kracht - CFO
- Patrick Brenske - MGB
- Marion Braun - SUB